High-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT) is an effective salvage therapy for patients with relapsed chemosensitive non-Hodgkin’s lymphoma (NHL). However, the optimal conditioning regimen is unclear. Different conditioning regimens prior to AHCT have been used with the two most common being BEAM (carmustine, etoposide, cytarabine, and melphalan) and BUCYVP16 (busulfan, cyclophosphamide, and etoposide). We sought to compare the two regimens for patients with relapsed NHL undergoing AHCT. We retrospectively compared the outcomes of patients treated with BEAM (N = 269) at The Ohio State University and BUCYVP16 (N = 409) at the Cleveland Clinic followed by AHCT between 2006 and 2014. The primary endpoints were progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR). Patient characteristics between the two groups were similar. After a median follow-up of 3.9 years for BEAM and 4.3 years for BUCYVP16 from AHCT, the rate of relapse (p = 0.69), PFS (p = 0.52), and OS (p = 0.11) were similar between the two conditioning regimens. No differences in survival outcomes were seen in disease subtypes. Multivariable analysis showed significant association toward improved OS with BEAM (HR: 1.56, 95% CI 1.16–2.10) (p < 0.01). Even though the study is limited by its retrospective nature and some differences in cohort, the findings indicate that BEAM could serve as an alternative conditioning regimen prior to AHCT for NHL.
BEAM and BUCYVP16 are equally effective as conditioning regimens prior to autologous stem cell transplant for non-Hodgkins lymphoma.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $89.17 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Armitage JO, Fyfe MA, Lewis J. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol. 1984;2:898–902. https://doi.org/10.1200/jco.19126.96.36.1998.
Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380:848–57. https://doi.org/10.1016/s0140-6736(12)60605-9.
MA S, DP H, JR A. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–94. https://doi.org/10.1056/nejm199309303291402.
Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5. https://doi.org/10.1056/nejm199512073332305.
Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373–80. https://doi.org/10.1200/jco.2009.26.2493.
Caballero MD, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20:451–8. https://doi.org/10.1038/sj.bmt.1700913.
Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:588–95. https://doi.org/10.1200/jco.19188.8.131.528.
Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW, et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2000;25:1243–8. https://doi.org/10.1038/sj.bmt.1702433.
Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin’s lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. J Clin Oncol. 1998;16:48–55. https://doi.org/10.1200/jco.19184.108.40.206.
Sakellari I, Mallouri D, Batsis I, Apostolou C, Konstantinou V, Abela EM, et al. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. Leuk Lymphoma. 2015;56:3071–81. https://doi.org/10.3109/10428194.2015.1028054.
Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F, et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol. 2002;81:96–102. https://doi.org/10.1007/s00277-001-0413-8.
Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant. 2006;12:770–7. https://doi.org/10.1016/j.bbmt.2006.03.016.
Andion M, Molina B, Gonzalez-Vicent M, Alonso L, Hernandez C, Lassaletta A, et al. High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study. J Pediatr Hematol Oncol. 2011;33:e89–91. https://doi.org/10.1097/MPH.0b013e3181fd6c79.
Dean RM, Pohlman B, Sweetenham JW, Sobecks RM, Kalaycio ME, Smith SD, et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol. 2010;148:226–34. https://doi.org/10.1111/j.1365-2141.2009.07940.x.
Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2007;40:919–24. https://doi.org/10.1038/sj.bmt.1705841.
Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant. 2004;34:581–7. https://doi.org/10.1038/sj.bmt.1704637.
Zaucha R, Gooley T, Holmberg L, Gopal AK, Press O, Maloney D, et al. High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma. 2008;49:1899–906. https://doi.org/10.1080/10428190802340184.
Jantunen E, Kuittinen T, Nousiainen T. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin’s lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma. 2003;44:1151–8. https://doi.org/10.1080/1042819031000083028.
Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS, et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res. 2011;35:183–7. https://doi.org/10.1016/j.leukres.2010.07.016.
Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, et al. Efficacy of pharmacokinetics-directed busulfan, cyclophosphamide, and etoposide conditioning and autologous stem cell transplantation for lymphoma: comparison of a multicenter phase II study and CIBMTR outcomes. Biol Blood Marrow Transplant. 2016;22:1197–205. https://doi.org/10.1016/j.bbmt.2016.03.018.
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM. et al. NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17:1244 https://doi.org/10.1200/jco.19220.127.116.114.
Vose JM, Rizzo DJ, Tao-Wu J, Armitage JO, Bashey A, Burns LJ, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant. 2004;10:116–27. https://doi.org/10.1016/j.bbmt.2003.09.015.
Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s Lymphomas: report of the jury. J Clin Oncol. 1999;17:423–9. https://doi.org/10.1200/jco.1918.104.22.1683.
Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30:4462–9. https://doi.org/10.1200/jco.2012.41.9416.
Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009;20:1985–92. https://doi.org/10.1093/annonc/mdp237.
Hill BT, Rybicki L, Carlstrom KD, Jagadeesh D, Gerds A, Hamilton B, et al. Daily weight-based busulfan with cyclophosphamide and etoposide produces comparable outcomes to four-times-daily busulfan dosing for lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:1588–95. https://doi.org/10.1016/j.bbmt.2016.06.011.
YE and SS designed research study; SS and QZ analyzed the results; NS and YE wrote the paper; PE, DA, and SS collected the data; MK, SD, and NM edited and provided scientific discussions; RD, CH, DB, AR, SP, LA, SV, SJ, BW, BB, BP, DJ, BH, and RS all reviewed and provided scientific discussions.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.